GlassScriptPhysician profile
Robert Edward Kneisley
NPI 1679598163
$2,119.52
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $260 · 2021: $16.04 · 2022: $39.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $338.73 | 2019-2020 | |
| Novo Nordisk INC | $261.38 | 2019-2022 | |
| Glaxosmithkline, LLC. | $160.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $146.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.06 | 2019-2020 | |
| Amgen INC. | $137.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $136.34 | 2019-2022 | |
| Astellas Pharma US INC | $105.01 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.80 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $88.25 | 2019 | |
| Abbvie INC. | $81.92 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.47 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $51.80 | 2019 | |
| Allergan, INC. | $33.88 | 2019-2020 | |
| Horizon Therapeutics Plc | $32.76 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $29.79 | 2019 | |
| Amarin Pharma, INC. | $29.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.61 | 2019 | |
| Lilly USA, LLC | $23.17 | 2019-2022 | |
| Radius Health, INC. | $17.42 | 2020 | |
| Supernus Pharmaceuticals, INC. | $17.27 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.66 | 2019 | |
| Biogen, INC. | $15.55 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.21 | 2019 | |
| Abbott Laboratories | $12.96 | 2020 | |
| Circassia INC. | $12.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kneisley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.